Menopause Treatment Algorithm by Line of Therapy

How Menopause Is Diagnosed Before Treatment Begins

Menopause is a clinical diagnosis. In women aged 45 or older, 12 consecutive months of amenorrhea with vasomotor symptoms confirms the diagnosis without laboratory testing, per NICE guideline NG23 (updated 2019) [1]. Routine FSH measurement is unnecessary in this population and can mislead clinicians during the erratic hormonal fluctuations of perimenopause.

For women aged 40 to 45 with irregular cycles and VMS, a single serum FSH above 25 IU/L on two occasions four to six weeks apart supports the diagnosis [1]. Women under 40 with suspected premature ovarian insufficiency require a separate workup including karyotype and adrenal antibody testing, as the Endocrine Society's 2015 clinical practice guideline specifies [2]. The 2022 NAMS position statement reinforces that the decision to treat should rest on symptom burden rather than a specific hormone threshold [3]. A woman reporting ten or more moderate-to-severe hot flashes per day needs intervention regardless of her FSH value.

Baseline evaluation before prescribing systemic hormone therapy includes blood pressure, BMI, breast cancer risk assessment (Gail or Tyrer-Cuzick model), and cardiovascular risk screening. Mammography should be current per USPSTF recommendations [4]. This pre-treatment checklist determines which line of therapy a patient enters.

First-Line Therapy: Systemic Hormone Therapy

Systemic estrogen, with a progestogen added for women with an intact uterus, is the most effective treatment for moderate-to-severe VMS. The 2022 NAMS position statement grades it as Level I evidence [3]. Oral conjugated equine estrogens (CEE) 0.625 mg daily reduced hot flash frequency by 75% versus 36% for placebo in the original Women's Health Initiative (WHI) cohort [5].

The critical variable is timing. The "timing hypothesis," confirmed by the 2017 reanalysis of WHI data published in JAMA, showed that women who initiated HT within 10 years of menopause onset had a hazard ratio for coronary heart disease of 0.76 (95% CI 0.50 to 1.16), while those starting more than 20 years post-menopause had a hazard ratio of 1.28 (95% CI 0.83 to 1.96) [6]. The Endocrine Society's 2015 guideline codified this window, recommending systemic HT initiation before age 60 or within 10 years of menopause [2].

Standard dosing options include oral estradiol 1 mg daily, transdermal estradiol 0.05 mg patch twice weekly, or CEE 0.625 mg daily. Transdermal delivery avoids first-pass hepatic metabolism, which reduces VTE risk. The ESTHER study (case-control, N=881) found that transdermal estrogen carried no excess VTE risk (OR 0.9 to 95% CI 0.5 to 1.6) compared with an OR of 4.2 for oral estrogen [7]. For women with elevated thrombotic risk or triglycerides above 300 mg/dL, transdermal is the preferred route.

Progestogen options for endometrial protection include micronized progesterone 200 mg nightly for 12 days per cycle (cyclic) or 100 mg nightly (continuous). The REPLENISH trial (N=1,845) confirmed that TX-001HR (estradiol/progesterone combination capsule) reduced VMS frequency by 78% at 12 weeks [8]. Levonorgestrel IUD provides endometrial suppression while avoiding systemic progestogen side effects. Short sentences work here: pick the progestogen by side-effect profile. Micronized progesterone carries the lowest breast cancer signal.

Second-Line Therapy: Non-Hormonal Pharmacologic Options

When systemic HT is contraindicated or declined, non-hormonal agents form the second tier. Fezolinetant, a neurokinin-3 (NK3) receptor antagonist, received FDA approval in May 2023 based on the SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials [9]. In SKYLIGHT 2 (N=501), fezolinetant 45 mg daily reduced moderate-to-severe VMS frequency by 61.6% at week 12 versus 40.7% for placebo (P<0.001) [9]. It does not carry estrogen-related risks, making it suitable for breast cancer survivors.

Paroxetine mesylate 7.5 mg (Brisdelle) is the only SSRI with FDA approval specifically for VMS. A pooled analysis of two phase 3 trials (combined N=1,175) showed a reduction of 1.66 hot flashes per day versus 1.18 for placebo at 12 weeks [10]. Venlafaxine 75 mg daily, though off-label, demonstrated comparable efficacy in a randomized trial (N=339) with a 61% reduction in hot flash scores at 4 weeks [11].

Other second-line agents include gabapentin 900 mg daily (divided doses), which reduced hot flash composite scores by 54% in a randomized trial (N=420) compared with 31% for placebo [12]. Gabapentin is particularly useful for women with concurrent insomnia, as the nighttime dosing exploits its sedative effect. Oxybutynin 2.5 mg twice daily demonstrated a 72% mean reduction in VMS at 12 weeks in a smaller crossover trial (N=150), though anticholinergic side effects limit its use in older adults [13].

The Endocrine Society's guideline ranks these agents as second-line with moderate-quality evidence, noting that none match the efficacy of estrogen for severe VMS [2]. The choice among them depends on the patient's comorbidity profile: SSRIs for concurrent mood symptoms, gabapentin for sleep disruption, fezolinetant for patients who want targeted VMS control without off-target CNS effects.

Third-Line and Adjunctive Therapies

Third-line options apply to patients with refractory symptoms after adequate trials of first- and second-line agents, or to those with specific clinical scenarios that limit drug selection. Clonidine 0.1 mg twice daily produces modest VMS reduction (38% versus 24% placebo) per a Cochrane review of 10 trials, but hypotension and dry mouth restrict tolerability [14]. Its role is limited to women who cannot use estrogen, NK3 antagonists, or centrally acting agents.

Stellate ganglion block (SGB), an interventional procedure, has shown promise in pilot studies. A sham-controlled trial (N=40) found a 52% reduction in moderate-to-severe hot flashes at 6 months post-procedure, but sample sizes remain small and the 2022 NAMS statement does not yet endorse it outside research settings [3]. Cognitive behavioral therapy (CBT) reduced hot flash interference scores by 50% in the MENOS 1 trial (N=96), addressing the distress component without reducing physiological flash frequency [15].

For sleep disturbance that persists despite VMS control, low-dose suvorexant 10 mg or lemborexant 5 mg may be added. Weight-bearing exercise plus vitamin D 800 IU daily are non-pharmacologic adjuncts recommended by ACOG for all menopausal women regardless of treatment tier [16].

Treating Genitourinary Syndrome of Menopause

GSM affects up to 84% of postmenopausal women, per a 2019 multinational survey published in Menopause [17]. Unlike VMS, GSM does not resolve spontaneously. It worsens over time without treatment.

Low-dose vaginal estrogen is first-line for GSM and can be prescribed independently of systemic HT decisions. The 2022 NAMS position statement confirms that vaginal estradiol 10 mcg tablets, estradiol cream 0.5 g, or the estradiol ring (Estring, releasing 7.5 mcg/day) produce minimal systemic absorption, with serum estradiol remaining in the postmenopausal range [3]. Endometrial surveillance and progestogen co-therapy are not required with these low-dose formulations.

Ospemifene 60 mg daily, an oral SERM, is FDA-approved for moderate-to-severe dyspareunia due to GSM. In a phase 3 trial (N=826), ospemifene improved vaginal dryness severity by 1.3 points versus 0.8 for placebo on a 4-point scale at 12 weeks [18]. Prasterone (intravaginal DHEA 6.5 mg nightly) offers a non-estrogen alternative, converting locally to both estrogen and androgen, which may benefit libido as well [19].

"For most women with GSM symptoms, we recommend starting vaginal estrogen before considering systemic therapy, as local treatment carries a far more favorable risk profile," states the 2017 Endocrine Society guideline on menopausal HT [2].

Bone Protection Within the Menopause Treatment Algorithm

Bone loss accelerates during the menopause transition: women lose 1.5% to 2.5% of bone mineral density (BMD) per year in the first 5 to 7 years postmenopause [20]. Systemic HT, if already prescribed for VMS, confers bone protection as a secondary benefit. The WHI demonstrated a 34% reduction in hip fracture (HR 0.66 to 95% CI 0.45 to 0.98) with CEE plus medroxyprogesterone acetate [5].

For women not on systemic HT, the USPSTF recommends screening with DXA at age 65 or earlier if the FRAX 10-year major osteoporotic fracture risk exceeds 8.4% [4]. First-line pharmacologic bone protection for women with T-scores at or below -2.5 includes alendronate 70 mg weekly or risedronate 35 mg weekly. The FLEX trial (N=1,099) showed sustained fracture reduction after 10 years of alendronate [21].

Denosumab 60 mg subcutaneously every 6 months is second-line or an option for bisphosphonate-intolerant patients. The FREEDOM trial (N=7,868) demonstrated a 68% relative risk reduction in vertebral fractures at 36 months [22]. For severe osteoporosis with existing fractures, anabolic-first sequencing with romosozumab 210 mg monthly for 12 months followed by an antiresorptive is now recommended per the 2020 AACE/ACE guideline [23].

"The 2020 AACE/ACE guideline recommends anabolic-first therapy for patients at very high fracture risk, including those with a recent vertebral fracture or T-score below -3.0," per the guideline's executive summary [23].

Monitoring and Duration of Therapy

No single monitoring protocol fits all menopausal women. Reassess symptoms and risk factors annually. The 2022 NAMS position statement does not impose a mandatory stopping point for HT but recommends periodic reevaluation using the lowest effective dose [3].

For VMS, a step-down trial (reducing dose by 50% for 3 to 6 months) can determine whether symptoms have resolved. The SWAN study found that 20% of women still experience VMS 10 years after their final menstrual period, so long-term therapy is clinically appropriate for some patients [24]. Breast cancer screening should continue per USPSTF guidelines, with no change in mammography interval due to HT use [4].

Bone density monitoring via DXA every 1 to 2 years is reasonable while on therapy, and a repeat DXA 1 to 2 years after discontinuation detects rebound bone loss, particularly after denosumab cessation. Lipid panels and fasting glucose should be checked annually, as the menopause transition independently increases cardiovascular risk markers.

For fezolinetant, liver function tests (ALT, AST, bilirubin) are required before initiation, at 3 months, at 6 months, at 9 months, and then periodically per the FDA label [9]. Discontinue if ALT or AST exceeds 5 times the upper limit of normal.

Putting the Algorithm Together: A Decision Framework

The treatment algorithm flows through three decision gates. First gate: are vasomotor symptoms moderate to severe? If yes and the patient is within the timing window (under 60 or within 10 years of menopause) with no contraindications, start systemic HT with transdermal estradiol preferred for those with elevated VTE or metabolic risk.

Second gate: if HT is contraindicated or refused, offer fezolinetant 45 mg daily or paroxetine 7.5 mg daily as second-line. Select gabapentin 900 mg daily if insomnia predominates. Third gate: for refractory cases, add CBT, consider stellate ganglion block in a research-capable center, or combine a second-line agent with low-dose HT if partial contraindication was the barrier.

Parallel to this VMS algorithm, assess GSM independently. Treat with vaginal estrogen or ospemifene regardless of the VMS track. Assess fracture risk at every visit, and layer bone-protective therapy according to DXA-derived T-score and FRAX output. Annual reassessment determines whether dose adjustment, agent switching, or a step-down trial is warranted.

The Women's Health Initiative follow-up data at 18 years (published 2020 in JAMA, N=27,347) confirmed no increase in all-cause mortality with prior HT use (HR 0.99 to 95% CI 0.94 to 1.03), providing long-term safety reassurance for patients and clinicians working through this algorithm [25].